# Adversarial Review — Iteration 8

**Rating: 8.6 / 10** (previous: 8.4)

**Trajectory:** 5.5 → 6.5 → 7.0 → 7.5 → 7.8 → 8.1 → 8.4 → **8.6**

---

## Summary

The paper has matured considerably. The reconciliation paragraph resolving the Finding 1 vs. Finding 3 tension is well-executed—framing the dissociation as the paper's point rather than a contradiction is the correct move. The 27-edge limitation is now honestly discussed. The title is tighter. The abstract reads as a coherent narrative rather than a list.

The remaining issues are minor but real. None individually would cause rejection at NMI, but collectively they represent polish that separates "accept with minor revisions" from "accept."

---

## What Would Still Cause Rejection (or Major Revision Requests)

### 1. The 27-Edge Elephant Is Acknowledged But Not Solved (Medium Risk)
The limitation paragraph on the 27-edge TRRUST set is honest, but a harsh reviewer could still argue the entire cross-tissue replication story (Core Finding 3) rests on an evaluation set too small for meaningful inference. Bootstrap CIs of ±0.03–0.05 mean the true AUROC could plausibly be 0.67–0.77. The DoRothEA mitigation (123 edges, AUROC ~0.84) helps, but a reviewer could note that DoRothEA includes ChIP-seq-derived edges that may be constitutively bound (not functionally active), inflating apparent performance.

**Fix:** Add one sentence noting that the 0.84 DoRothEA AUROC should be interpreted as an upper bound since ChIP-seq binding does not guarantee functional regulation. This preempts the critique.

### 2. No Permutation Null for Cross-Tissue AUROC (Medium Risk)
Table 5 shows AUROC ~0.72 across tissues, but there's no permutation baseline showing what AUROC random edge scores achieve against these 27 edges. With only 27 positives out of ~720K possible pairs (1200 choose 2), even modest ranking biases (e.g., hub genes receiving higher attention) could produce inflated AUROC. The paper never reports a shuffled-label null for this specific evaluation.

**Fix:** Report the permutation-null AUROC (shuffle TRRUST labels 1000×) for the 27-edge set. If it's 0.50±0.03, you're fine. If it's 0.55+, the finding weakens.

### 3. Single-Author Credibility Gap (Low-Medium Risk)
NMI reviewers may question whether one person ran all 12 analyses rigorously. The code/data availability sections say "available upon acceptance," which is standard but doesn't help reviewers verify now. This is a soft risk—not a technical flaw, but a trust issue.

**Fix:** Make the repository available to reviewers immediately (anonymous link). State this explicitly.

### 4. The Custom Synthetic Generator Remains a Weakness (Low-Medium Risk)
The justification for not using SERGIO is well-argued but still amounts to "we needed a generator aligned with our theory." A skeptic reads this as "we built a generator that confirms our predictions." The 91% Shapley improvement and the scaling failure curves are only as credible as the synthetic setup.

**Fix:** Already mitigated by the honest caveat in Section 4.10. No further action needed, but expect a reviewer comment here.

### 5. Scope Creep: 9 Supporting Analyses Dilute Focus (Low Risk)
The paper is long. The 3-core + 9-supporting structure is clear, but some supporting analyses (detectability theory, calibration) are essentially standalone papers compressed into subsections. A reviewer may request moving 3-4 supporting analyses to supplementary material to tighten the main text.

**Fix:** Preemptively offer (in cover letter) to move Sections 3.5 (detectability), 3.9 (calibration), and 3.7 (ortholog) to supplementary if space is a concern. Keep the core 3 + scaling + batch + baselines in main text.

---

## Minor Issues

1. **Abstract length.** Still ~220 words. NMI typically expects ≤150. Trim the supporting analysis sentence ("These findings are supported by comprehensive quality-control analyses spanning...") entirely—it adds no information a reviewer needs in the abstract.

2. **Table 5 formatting.** The cross-tissue table has 6 decimal places of near-identical numbers (0.718 vs 0.716 vs 0.716). This invites the critique "you're reporting noise." Round to 2 decimal places and emphasize the consistency narrative rather than precise values.

3. **"Reconciling" paragraph placement.** Currently in Discussion 4.1. Consider moving a condensed version to the transition between Core Finding 1 and Core Finding 2 in Results, where the reader first encounters the apparent tension. By the time they reach Discussion, the concern may have already hardened into a negative impression.

4. **Missing effect size for co-expression correlation.** You report ρ = 0.31–0.42 with regulatory ground truth but don't report the partial correlation controlling for co-expression. If attention correlates with co-expression (ρ ~ 0.35) and regulation correlates with co-expression (even weakly), the zero regulatory correlation could be a suppression effect. Reporting partial correlations (attention–regulation | co-expression) would be more informative.

5. **The phrase "the paper's central point, not a contradiction"** in the reconciliation paragraph is slightly defensive. Rephrase to something like "this dissociation between pooled and stratified evaluation is the core diagnostic insight" — same content, less defensive tone.

---

## What's Working Well

- **Narrative arc** is now clean: attention ≠ regulation → but stratification recovers signal → and it replicates across tissues.
- **Honesty about limitations** is exemplary (27-edge caveat, power limitations, synthetic generator caveats, circularity paragraph).
- **The reconciliation paragraph** successfully resolves what was the biggest structural weakness.
- **Framework-level FDR correction** across 47 tests is rigorous and uncommon—reviewers will appreciate this.
- **Cross-model convergence** (scGPT + Geneformer + scVI + C2S-Pythia) strengthens the generality claim.

---

## Verdict

**8.6/10.** The paper is now in "accept with minor revisions" territory for NMI. The two medium-risk issues (#1 DoRothEA upper-bound caveat, #2 permutation null for cross-tissue) are straightforward fixes that would push this to 8.8–9.0. The scope/length issue may trigger a "move to supplement" request but won't cause rejection.

The diminishing returns in the review trajectory (Δ = +0.2) reflect that the paper is approaching its ceiling given the fundamental constraint of the 27-edge evaluation set. That constraint can only be fully resolved with additional wet-lab or larger-scale computational validation, which is future work.
